Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Despite Its High P/E Ratio, Is Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Still Undervalued?
01:18pm, Monday, 13'th Apr 2020
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). To keep it practical, we'll...
Citigroup Cuts Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $71.00
10:08am, Monday, 13'th Apr 2020
Ionis Pharmaceuticals (NASDAQ:IONS) had its target price cut by Citigroup from $73.00 to $71.00 in a report issued on Thursday morning, BenzingaRatingsTable reports. They currently have a buy rating o
Athenex (ATNX) Receives a Buy from Needham
02:59pm, Thursday, 09'th Apr 2020
Needham analyst Chad Messer reiterated a Buy rating on Athenex (ATNX) today and set a price target of $30.00. The company's shares closed last Thursday at
Athenex (ATNX) Receives a Buy from Needham
02:59pm, Thursday, 09'th Apr 2020
Needham analyst Chad Messer reiterated a Buy rating on Athenex (ATNX – Research Report) today and set a price target
AQR Capital Management LLC Sells 10,652 Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS)
08:32am, Thursday, 09'th Apr 2020
AQR Capital Management LLC trimmed its position in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 43.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Ex
Aeglea Biotherapeutics (AGLE) Receives a Buy from Needham
06:24pm, Wednesday, 08'th Apr 2020
In a report released today, Chad Messer from Needham reiterated a Buy rating on Aeglea Biotherapeutics (AGLE), with a price target of $14.00. The
Aeglea Biotherapeutics (AGLE) Receives a Buy from Needham
06:24pm, Wednesday, 08'th Apr 2020
In a report released today, Chad Messer from Needham reiterated a Buy rating on Aeglea Biotherapeutics (AGLE – Research Report),
Why Ionis Pharmaceuticals (IONS) Stock Might be a Great Pick
01:56pm, Wednesday, 08'th Apr 2020
Ionis Pharmaceuticals (IONS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
Why Ionis Pharmaceuticals (IONS) Stock Might be a Great Pick
01:56pm, Wednesday, 08'th Apr 2020
Ionis Pharmaceuticals (IONS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
Ionis establishes $25,000 scholarship to help ALS patients in greater San Diego area participate in physical and mental wellness programs
11:05am, Wednesday, 08'th Apr 2020
Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, today announced that it has established a $25,000 scholarship to help ALS patients in the greater San Diego area participate in a
FDA extends action date for Roche's risdiplam for spinal muscular atrophy
08:31pm, Tuesday, 07'th Apr 2020
Citing the submission of additional data that it considered a major amendment, the FDA has extended the action date for its review of Roche (OTCQX:RHHBY) unit Genentech's marketing application seeking
Despite Its High P/E Ratio, Is Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Still Undervalued?
01:59pm, Tuesday, 07'th Apr 2020
Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. We'll show how you can...
Ionis Pharmaceuticals to present at upcoming investor conferences
11:05am, Tuesday, 07'th Apr 2020
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences:
Needham Thinks Esperion's Stock is Going to Recover
03:08pm, Monday, 06'th Apr 2020
In a report released today, Chad Messer from Needham reiterated a Buy rating on Esperion (ESPR), with a price target of $158.00. The company's shares
Needham Thinks Esperion’s Stock is Going to Recover
03:08pm, Monday, 06'th Apr 2020
In a report released today,
Chad Messer
from Needham reiterated a
Buy
rating on Esperion (
ESPR
–
Research Report
), with a price target of
$158.00
. The company’s shares closed last Monday at $32
